logo
Plus   Neg
Share
Email

Merck: KEYTRUDA Approved For New Indication In China - Quick Facts

Merck (MRK) said KEYTRUDA, the company's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China as monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 as determined by a fully validated test, following failure of one prior line of systemic therapy. The company noted that, with the new approval, KEYTRUDA is now approved for five indications across three different types of cancer in China.

Separately, Merck reported results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal conjugate vaccine. The company said V114 met safety and immunogenicity objectives in initial phase 3 studies in adults. The company plans to continue to work with the FDA and other regulatory authorities around the world on filing plans for licensure of this vaccine as more data from the Phase 3 program become available.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of BMW AG were losing around 5 percent in German trading after the luxury car maker reported Wednesday a loss in its second quarter, compared to prior year's profit as demand was hit hard by coronavirus pandemic. Looking ahead, the company said it is cautiously optimistic for second half of the year, and reaffirmed fiscal 2020 outlook. Billionaire Richard Branson's Virgin Atlantic has filed for Chapter 15 bankruptcy protection in the United States after being hit hard by travel restrictions due to the coronavirus pandemic. The process is part of the British airline's restructuring plan as it is seeking a 1.2 billion pounds rescue deal in the U.K. The airline also filed a proceeding in the high court in London for its restructuri Humana Inc. (HUM) reported second quarter adjusted earnings per share of $12.56 compared to $6.05, previous year. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $10.27, for the quarter. Analysts' estimates typically exclude special items. Second...
Follow RTT